Pfizer’s COX-2 Scripts Take More Hits From Kaiser
This article was originally published in The Tan Sheet
Executive Summary
A decision by Kaiser Permanente physicians in California to stop prescribing Bextra demonstrates the challenges Pfizer must overcome as it seeks to reassure the public about the cardiovascular safety of COX-2 inhibitors